Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study.
about
Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy?Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot studyAdditional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse modelA comprehensive dosimetric study on switching from a Type-B to a Type-C dose algorithm for modern lung SBRTSurvey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR ConsortiumRadiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite.GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms.Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidityThe role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms.Alternatives to surgery in early stage disease-stereotactic body radiotherapyPulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversiesSpinal radiosurgery--efficacy and safety after prior conventional radiotherapyAdapted Prescription Dose for Monte Carlo Algorithm in Lung SBRT: Clinical Outcome on 205 Patients.Dosimetric verification using monte carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy.The effect of beam arrangements and the impact of non-coplanar beams on the treatment planning of stereotactic ablative radiation therapy for early stage lung cancer.Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes.Volumetric intensity-modulated arc therapy vs conventional intensity-modulated radiation therapy in nasopharyngeal carcinoma: a dosimetric study.Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study.Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trialComparing the clinical outcomes in stereotactic body radiotherapy for lung tumors between Ray-Tracing and Monte-Carlo algorithms.Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer.Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors.Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer.Marginal prescription equivalent to the isocenter prescription in lung stereotactic body radiotherapy: preliminary study for Japan Clinical Oncology Group trial (JCOG1408)A contemporary review of stereotactic radiotherapy: inherent dosimetric complexities and the potential for detriment.Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges.Clinical introduction of Monte Carlo treatment planning for lung stereotactic body radiotherapy.Correlation between target volume and electron transport effects affecting heterogeneity corrections in stereotactic body radiotherapy for lung cancer.Lung cancer. Radiotherapy in lung cancer: Actual methods and future trends.Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?Recurrence after surgery in patients with NSCLC.Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription.The development of stereotactic body radiotherapy in the past decade: a global perspective.Stereotactic ablative body radiotherapy for non-small-cell lung cancer: setup reproducibility with novel arms-down immobilization.Stereotactic radiotherapy of intrapulmonary lesions: comparison of different dose calculation algorithms for Oncentra MasterPlan®Evaluation of pencil beam convolution and anisotropic analytical algorithms in stereotactic lung irradiation.
P2860
Q26853124-BBC724DB-D0D4-4E6C-805A-8F37CCCAFCABQ28083924-E246850F-2DB7-4CC2-B7FD-86534E6A5F8EQ30474874-E56EE7D8-AF56-4048-BFFC-63BB36AC01B7Q30993385-BA8727D2-AC59-435C-8AF7-78AA9A2EAC3BQ31075401-C51A0793-8F3A-48D1-9126-92CC16C26D33Q33574341-C73619FC-6343-4394-9685-7178FE997752Q33644800-67918714-48A5-42DB-BD33-1C882BAD533EQ33823049-371F740C-0E3F-4E6B-9053-7227BE7B0AEAQ34211377-8072B38D-E087-424A-B493-3868F84A41BEQ34381901-E7FF3238-606A-4E62-B3CE-704AD80D8CD0Q34859171-A39A3623-3838-4799-B7EA-CCD26934FAD5Q35113011-1DDDCF4C-A9FE-4771-B459-2978E34FD6A9Q35200644-5AAE6D30-936A-4A29-9678-BA3CFD140D9CQ35565178-666DF4D6-6F3D-4CC3-9888-B717C389F5E9Q35667829-D5A46DA8-2D62-45A8-911D-6AC740D365F1Q35690484-40B309CB-8A20-4839-9313-F6BA61326E67Q35710889-3B87067E-6596-45EE-91BA-700BE4F2DC81Q36010763-1D2CE563-70EC-469A-8326-1E156D09070EQ36644220-12830F86-099F-420E-81E8-40A8D87279C1Q36753846-F23D3DCA-331D-4EF6-8440-7450A6498433Q36833682-5A975FB8-3E28-4705-AF34-BFBB44142B22Q36843349-928A28BC-DB6D-44B5-AA87-356B2E3E7101Q36980782-CF935E6B-6467-4AB0-B457-66A9AFE02A3DQ37109928-07C57043-AE79-4077-BD60-C2D81CC3EE2EQ37307675-AB5ABA37-9C3A-471F-9676-2473A899928BQ37392508-0C1C4351-E08C-4216-87E9-D6C3D0527BE8Q37468265-E03DBBB0-D4CF-414F-AB69-579F425EDE0EQ37659318-9E6FC39C-9474-4639-9B97-6311AAAD9512Q37834640-ABFB6A2C-2D4A-4150-BC95-D6D062629A52Q37993783-0A29DDE0-F079-4AE6-9453-1459BB403BC0Q38178429-1D85B1EB-9368-4A87-BADA-694AA18DDDECQ38187550-86F56DEB-0F6B-4000-B3A7-06E538C08221Q38261944-BD830821-B86A-4A6E-87CF-705D7C0116DDQ38367507-7A35A2BC-88E4-4A3B-8694-5DBE11ACB3C4Q38390164-546C62A1-DFD7-43F6-A9E4-05A195E3800FQ38609742-5C645838-B158-47D2-8FD2-4EAC587F1601Q38967475-6B9A6E58-9310-4313-9FBF-32C2E8155557Q39319814-FE5E1A57-46C2-4406-9932-4C1BB1AAF80DQ39320180-5B909543-A57C-4F2B-8CEC-9F2F17ADAB91Q40105418-C687276E-8868-44A4-9ECB-964A56D571BC
P2860
Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Recommendations for implementi ...... domised phase III ROSEL study.
@en
type
label
Recommendations for implementi ...... domised phase III ROSEL study.
@en
prefLabel
Recommendations for implementi ...... domised phase III ROSEL study.
@en
P2093
P2860
P50
P356
P1433
P1476
Recommendations for implementi ...... domised phase III ROSEL study.
@en
P2093
Coen W Hurkmans
Frank J Lagerwaard
Johan P Cuijpers
Uulke A van der Heide
P2860
P2888
P356
10.1186/1748-717X-4-1
P577
2009-01-12T00:00:00Z
P6179
1042115934